BURLINGTON, N.C. – October 23, 2025 Labcorp (NYSE: LH), a global leader in laboratory diagnostics, announced it will soon offer the first FDA-cleared blood test to aid in ruling out Alzheimer’s-related amyloid pathology directly in primary-care settings. The Elecsys® pTau181 test, developed by Roche Diagnostics, is intended for adults aged 55 and older showing cognitive decline. Labcorp plans nationwide availability by early 2026, marking a breakthrough in how Alzheimer’s is assessed and managed at the initial point of care.
Science Significance
The Elecsys pTau181 test measures phosphorylated tau 181 (pTau181) in human plasma — a key biomarker for Alzheimer’s pathology associated with amyloid plaque and tau aggregation in the brain. Clinical evaluations demonstrated a 97.9% negative predictive value, allowing clinicians to confidently rule out amyloid pathology when results are negative. The test aligns with the latest biomarker-based models of neurodegenerative disease, providing a less invasive, scientifically robust alternative to lumbar puncture or PET imaging. This technology represents a paradigm shift toward blood-based neurology diagnostics, bringing molecular precision to everyday clinical practice.
Regulatory Significance
The FDA clearance of the Elecsys pTau181 test signifies an important regulatory milestone in neurodegenerative diagnostics. It validates the test’s clinical accuracy and safety for use in identifying Alzheimer’s-related amyloid pathology. This clearance extends the reach of regulated Alzheimer’s testing beyond specialized centers to primary-care physicians, improving early identification and patient triage. The decision reflects the FDA’s growing support for in-vitro diagnostic innovations that address national healthcare priorities in aging and cognitive decline.
Business Significance
Advertisement
For Labcorp, this launch reinforces its position as a market leader in neurology diagnostics. The company will leverage its network of over 2,200 patient service centers to make the test widely accessible, providing a scalable and cost-efficient solution for Alzheimer’s evaluation. Following the success of its earlier Lumipulse® pTau-217/Beta-Amyloid 42 Ratio assay, this new addition expands Labcorp’s portfolio of FDA-cleared and laboratory-developed Alzheimer’s tests, strengthening its competitive edge in precision medicine. It also highlights strategic collaboration with Roche Diagnostics, aligning both companies in advancing biomarker-driven healthcare.
Patients’ Significance
For millions of patients and families confronting cognitive decline, this new blood test represents a major advancement in accessibility and peace of mind. Instead of undergoing invasive spinal taps or costly imaging, patients can now receive a simple blood draw in a doctor’s office or at a Labcorp collection site. A negative result helps rule out Alzheimer’s pathology, allowing clinicians to focus on alternative causes of cognitive impairment, while positive results guide timely referral to specialists. The innovation empowers primary care providers to deliver earlier, more personalized care and supports faster diagnostic decision-making for patients experiencing memory loss.
Policy Significance
The FDA’s clearance of the Elecsys pTau181 test reflects broader public health and policy priorities emphasizing early detection, accessibility, and healthcare equity in neurodegenerative disease management. It aligns with U.S. initiatives to improve Alzheimer’s outcomes through biomarker-based diagnostics and value-based care models. The approval could influence future reimbursement frameworks and clinical guidelines, accelerating the adoption of blood-based diagnostics as part of national Alzheimer’s care strategies.
With the Elecsys pTau181 test, Labcorp and Roche have introduced a transformative diagnostic tool that brings Alzheimer’s biomarker testing into routine primary care for the first time. This development unites scientific rigor, regulatory validation, and clinical accessibility to meet an urgent public health need. As Labcorp rolls out the test nationwide in 2026, it is poised to reshape the diagnostic landscape, enabling earlier intervention, better resource allocation, and a higher standard of care for patients experiencing cognitive decline.
Source: Labcorp press release
